U.S. scientists helped devise the Crispr biotechnology tool. First to test it in humans are Chinese doctors.
The gene-editing tool’s potential to upend science is dizzying.
We now have the power to quickly and easily alter DNA. It could eliminate disease, It could solve world hunger. It could provide unlimited clean energy. It could really get out of hand - Amy Maxmen
CRISPR is actually a naturally-occurring, ancient defense mechanism found in a wide range of bacteria. As far as back the 1980s, scientists observed a strange pattern in some bacterial genomes.
The stakes couldn’t seem higher. This is a technology, we are told, that could rewrite life. The birth of a new industry. I even wrote, four years ago, that CRISPR could “change biotech forever.” And it could.
But that impact will happen more slowly than one would think from reading press releases.
Scientists hacked the machinery of cellular warfare to splice genes. Now they’ve found a way to guard against it, too.
A new gene-editing tool might create an ethical morass — or it might make revising nature seem natural.
Would you eradicate malaria-carrying insects? Change your baby’s DNA? Scientists soon may have the power to do both.
A powerful new technology enables us to manipulate our DNA more easily than ever before.
As has happened with research elsewhere, the CRISPR-edited embryos weren’t implanted—they were kept sustained for only a couple of days. So, while this research is an important building block for the future, it doesn’t mean the future is already here.
Genetic engineering is tricky business. Its potential for good, for bad, and for unintended consequences is almost unlimited. How do you realize the good while avoiding the bad?
CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform.
Our singular focus is on the advancement of new applications for CRISPR-Cas gene editing that will help bring the tremendous promise this technology holds for patients and consumers to reality.
Cellectis is focused on addressing the medical and food needs of an ever-growing global population through the use of proprietary gene-editing technologies. By leveraging the expertise of our management, research and clinical teams, we believe we can make strong advancements in the immuno-oncology and plant sciences fields.
Editas Medicine is building the leading genome editing company dedicated to treating patients with genetically defined diseases.
At Precision, leaders in genome editing utilize the ARCUS® editing platform to eliminate cancers, cure genetic diseases, and create safer, more productive food sources.
We are committed to translating ground-breaking science into genomic therapies that transform patients’ lives.